Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina

Jie Wang

Status and phase: Unknown; Phase 2

Conditions: Unstable Angina; Coronary Heart Disease

Treatments: Drug: Placebo oral capsule; Drug: Xuesaitong soft capsule

Study type: Interventional

Funder types: Other

Identifiers

NCT03083119

81473561

Details and patient eligibility

About

In this study, typical cases of coronary heart disease are selected. They will be intervened by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.

Enrollment: 70 estimated patients

Sex: All

Ages: 30 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of coronary angiography unstable angina
• Clinical diagnosis of unstable angina
• Age of 30 to 75 years old
• Not use thrombolysis, dilate coronary drugs within two weeks
• Sign the consent

Exclusion criteria

• Severe valvular heart disease
• Insulin-dependent diabetes
• mental disease
• Combined with severe liver, kidney, hematopoietic system disorder
• Patients with malignant tumors
• Pregnancy or breast-feeding women
• Recent history of trauma
• Drug allergy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

70 participants in 2 patient groups, including a placebo group

Xuesaitong soft capsule group

Experimental group

Description:

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.

Treatment:

Drug: Xuesaitong soft capsule

Placebo Comparator

Placebo Comparator group

Description:

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.

Treatment:

Drug: Placebo oral capsule